A strong team with experience and know-how

Management

Dr. Walter von Horstig - Vorstand
Dr. Walter von Horstig

Dr. Walter von Horstig

Dr. von Horstig studied business administration at the University of Mannheim and St. Gall, where he also completed his PhD thesis. From 1993 to 1998 he worked as a management consultant for Bain & Company and the ABB Group. From 1999 to 2004, Dr. von Horstig was founder, managing director and board member of several start-up companies in the service and biotech sector, before joining the Underberg Group as Commercial Director. From 2009 to the beginning of 2017, Dr. von Horstig was the Managing Director of a DRK blood donation service and was responsible for a fundamental economic restructuring of the company. In April 2017, he joined the M1 Med Beauty Berlin GmbH as Managing Director before being appointed to the Management Board of M1 Kliniken AG in October 2017.

Board

Dr. Albert Wahl
Uwe Zimdars
Prof. Dr. Dr. Sabine Meck

Latest news

| Investor News

  • Group revenue rises to EUR 237 million (EUR 82 million in Q3-2020)
  • Beauty: treatment numbers at high level; record revenue in German practice network in October 2021; no negative impact from rising incidence rate of the Corona pandemic
  • Group EBITDA amounts to EUR 13.3 million (previous year: EUR 8.8 million); EBIT amounts to EUR 9.1 million (previous year: EUR 5.8 million); EBIT margin in the German practice network in the target corridor of 15-20% despite large number of new openings

| Investor News

  • Significant expansion of site capacities in Germany and internationally
  • Sales in the "Beauty" segment well above the previous year's figures. Expected annual sales of over EUR 50 million in the Beauty segment in 2021

| Investor News

  • Group revenue rises to just under EUR 165 million (EUR 37 million in H1-
    2020)
  • Consolidated EBITDA amounts to EUR 9.9 million (previous year: EUR 1.7
    million); EBIT amounts to EUR 7.1 million (previous year: EUR -0.05
    million)
  • Beauty: Significant increase in treatment and sales figures; Coronarelated
    ‘idle capacity’ due to vaccination intervals

| Investor News

After the Corona-related restrictions of the previous year, the Management Board is confident about the development of the company in the current financial year and the future.